BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 8004664)

  • 1. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
    Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.
    Nikfardjam M; Graf S; Beckmann R; Hornykewycz S; Koller-Strametz J; Binder BR; Huber K
    Thromb Haemost; 1999 Sep; 82 Suppl 1():80-4. PubMed ID: 10695493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
    Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
    Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibrinolytic system in chronic renal failure.
    Lottermoser K; Petras S; Pöge U; Fimmers R; Hertfelder HJ; Schiermeyer B; Vetter H; Düsing R
    Eur J Med Res; 2001 Sep; 6(9):372-6. PubMed ID: 11591527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis.
    Petäjä J; Myllynen P; Rokkanen P; Nokelainen M
    Acta Chir Scand; 1989; 155(4-5):241-6. PubMed ID: 2508383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of erythropoietin on fibrinolysis in hemodialyzed patients].
    Opatrný K; Vít L; Opatrná S; Bodláková B; Sulková S; Opatrný K; Krist'an M
    Cas Lek Cesk; 1995 Mar; 134(5):136-8. PubMed ID: 7728837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells.
    Hu XY; Ma YH; Wang C; Yang YH
    Chin Med J (Engl); 2009 Oct; 122(19):2380-5. PubMed ID: 20079143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
    Keber I; Keber D; Stegnar M; Vene N
    Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective double-arm study of fibrinolysis in surgical patients.
    Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
    J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
    Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
    Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
    Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.